Utilization of a Computerized Intravenous Insulin Infusion
Program to Control Blood Glucose in the Intensive Care Unit
Rattan Juneja, Corbin Roudebush,
Nilay Kumar, Angela Macy, Adam
Golas,
Donna Wall, Cheryl Wolverton, Deborah
Nelson, Joni Carroll, Samuel J. Flanders.
Diabetes Technology &
Therapeutics.
Jun 2007, Vol. 9, No. 3:
232-240
Background: This proof of concept study was designed
to evaluate the safety and effectiveness of an intravenous
insulin dosing calculator, the Clarian GlucoStabilizer™
program, and to determine the feasibility of its use as part
of a glycemic control program. This paper discusses the
impact of the GlucoStabilizer program on the glycemic
control of intensive care patients with hyperglycemia.
Methods: Patients admitted to the intensive care unit
(ICU), requiring intravenous insulin, were treated using the
GlucoStabilizer program. This program calculates an insulin
drip rate based on the low and high blood glucose (BG)
levels of the desired target range, the patient's current
and previous BG levels, and an insulin sensitivity factor,
with a goal of safely and expeditiously achieving and
maintaining the patient's BG in the target range.
Results: From October 2004 through March 2006, the
GlucoStabilizer program has been used to treat 2,398
patients in the ICUs, with 177,279 BG measurements in its
database. In these patients:
-
61.0% of BGs have been in
the target range of 80–110 mg/dL.
-
90.9% have been in the wider
range of 60–150 mg/dL.
-
The average BG was 106.5 mg/dL
(SD 39.1 mg/dL).
-
The frequency of
hypoglycemia (BG <50 mg/dL) was 0.4%.
These results compare favorably with the level of glycemic
control in the 3 months before implementation of the
GlucoStabilizer program.
Conclusions: Use of the GlucoStabilizer program in
the ICU resulted in improved glycemic control compared to
the previous manually calculated glycemic control protocols.
Notes: The Clarian GlucoStabilizer™ is now being
commercially marketed by Medical Decisions Network as the
GlucoStabilizer™. For more information, click
here.
***For a copy of the complete
article,
click here.***
If you are a current subscriber of Diabetes Technology &
Therapeutics and would like to access the article
online,
click here.